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Introduction
The aims of chronic obstructive pulmonary disease (COPD) pharmacotherapy are to reduce symptoms, reduce the frequency and severity of exacerbations, and improve health status and exercise tolerance. 1 Bronchodilators, such as long-acting β2 agonists (LABAs) and long-acting anticholinergics, are often prescribed as monotherapy. 4 This study replicates the design of the Singh study with three important differences: 1) we recruited patients with a modified Medical Research Council (mMRC) score of 1 or more, making ours a study in a milder group of COPD patients in terms of symptoms, whereas Singh et al 4 recruited patients with a mMRC score greater than 1; 2) we used 250 µg FP not 500 µg; and 3) our treatment period was 28 days not 14 days.
Data regarding the use of SFC250 plus TIO in Japan are limited. Therefore, our aim was to compare the effects of SFC250 twice daily plus TIO once daily with the individual treatments on lung function and volume in Japanese COPD patients to provide further evidence to support the effect of "triple therapy" for appropriate patients. Figure 1 shows the study design with dosing regimen and period. Patients with COPD diagnosed according to current guidelines were recruited from February to June 2013 (last patient's last visit: November 2013) by three centers across Japan. Patients were aged 40-80 years (inclusive) and had a smoking history of .10 pack years, postbronchodilator forced expiratory volume in 1 second (FEV 1 ) $30% to #75% predicted normal, postbronchodilator FEV 1 /forced vital capacity (FVC) ratio ,70%, and mMRC Dyspnoea Scale score $1.
Patients and methods

Patient population
Exclusion criteria included a diagnosis of asthma; any respiratory disorder other than COPD; previous lung surgery; current pulmonary rehabilitation; regular long-term oxygen use $12 hours/day; exacerbation; use of parenteral, oral, or depot corticosteroids; change in COPD medication; use of 
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antibiotics in the 4 weeks before screening; or hospitalization within the past year for an exacerbation.
All patients gave written informed consent. The study protocol was approved by the appropriate institutional review boards (Asahikawa Medical Center Institutional Review Board; ID# 12-b-1, Ibarakihigashi National Hospital Institutional Review Board, and AMC Nishi-umeda Clinic Institutional Review Board), and the study was conducted in accordance with good clinical practice guidelines and the Declaration of Helsinki 2008.
study design
This was a randomized, double-blind, double-dummy, Williams square design crossover study.
14 Patients entered a 2-week washout period having discontinued all existing COPD medications. Eligible patients were then randomized to one of six treatment sequences ( Figure 1 ). Each patient received all three treatments of SFC250 twice daily plus TIO once daily, SFC250 twice daily, or TIO once daily, for 4 weeks. SFC250 was administered via Diskus™ inhaler (GlaxoSmithKline, Middlesex, UK), TIO via HandiHaler ® (Boehringer Ingelheim, Ingelheim, Germany). Two-week washout periods separated each treatment period. After randomization, only salbutamol was allowed in addition to the study medication.
Lung function measurements were performed on days 1 and 28 of each treatment period, and salbutamol was withheld for 6 hours premeasurement. Follow-up was 2 weeks after the end of treatment or study withdrawal. Total study duration was 20 weeks.
Patients were randomly assigned to a treatment sequence by site staff using the randomization schedule from the validated GlaxoSmithKline Registration and Medication Ordering System. Treatment compliance was assessed at each posttreatment visit by recording the number of doses remaining in each Diskus™ and the number of capsules remaining for each HandiHaler ® .
assessments Pulmonary function
Specific airway conductance (sGaw) and specific airway resistance (sRaw) were recorded pre-and postdose (30, 75, 120, and 240 minutes) on days 1 and 28 of each treatment period. FEV 1 , FVC, inspiratory capacity (IC), residual volume (RV), total lung capacity (TLC), and thoracic gas volume (TGV) were assessed pre-and postdose (120 and 240 minutes) on days 1 and 28 of each treatment period after sGaw was recorded. sGaw, FEV 1 , FVC, IC, and TGV were assessed using a constant volume plethysmograph (MasterScreen ® Body, eResearch Technology GmbH, Philadelphia, PA, USA); sRaw, TLC, and RV were calculated from these parameters. Triplicate measurements were recorded and the mean was used for analysis.
Diary cards and symptoms
Patients completed daily record cards to record the number of occasions they used rescue medication over a 24-hour period between the first dose on that day and the first dose on the next day.
safety
Adverse events (AEs) were documented at each visit; vital signs and 12-lead electrocardiograms were taken at screening only.
statistical methods
The treatment comparisons were SFC250 + TIO versus TIO and SFC250 + TIO versus SFC250 and were considered of equal importance. Based on previous data, 15 a 15% decrease in sGaw for the individual treatments compared with SFC250 + TIO was considered clinically relevant. To detect a 15% decrease in AUC 0-4h sGaw between one individual treatment and SFC250 + TIO with 90% power, a two-sided 0.025 significance level and a within-patient standard deviation of 0.1652 (log transformed sGaw) and to ensure $90% power to detect 15% difference in sRaw using a standard deviation of 0.1725, 48 randomized patients were needed; so, 36 patients completed $2 treatment periods.
The modified intent-to-treat (mITT) population was the primary population for the efficacy analysis ( Figure 2) .
The primary efficacy endpoint was postmorning dose, AUC 0-4h sGaw on day 28. sGaw AUC 0-4h was log transformed and analyzed using a mixed model with treatment, period, baseline, and mean baseline included as fixed effects, and patient fit as a random effect. Analyses were adjusted for baseline (log-transformed predose value on day 1 of each treatment period) and mean baseline (mean of the three baselines for each patient) to account for the patient's status at the beginning of each treatment. Denominator degrees of freedom were approximated and bias was corrected in the estimated variance-covariance matrix of the fixed effects. 16 Treatment ratios for the comparison of SFC250 + TIO with TIO and SFC250 were calculated from the antilog of the difference between least square means. The 97.5% and 95% confidence intervals were calculated using pooled estimates 
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saito et al of variance for the difference, and the antilog values were reported. Adjusted means and differences in logged data were converted to geometric mean ratios. An adjusted geometric mean ratio =1 indicated no difference between the treatments or time points compared; .1 indicated a positive difference, and ,1 indicated a negative difference. The 97.5% confidence interval was used to draw conclusions regarding the relative efficacy of the treatments to account for the two equally important treatment comparisons, with a P-value of ,0.025 being significant.
The 2-week washout period between treatment periods was considered sufficient to minimize carryover effects, so treatment by period interaction and carryover effects were not formally investigated.
Secondary end points, FEV 1 , FVC, IC, RV, TLC, TGV, and postdose sRaw and sGaw, were analyzed in a similar way to the primary efficacy parameter, although FEV 1 and FVC were not log transformed prior to analysis. Analyses for days 1 and 28 were performed separately. The number of occasions salbutamol was used as rescue medication in a 24-hour period was recorded. All on-treatment AEs were summarized. Events with onset during the washout and follow-up periods were considered to have onset on the previously received treatment.
Results
Patient demographics and disposition
Patient demographic and baseline characteristics are summarized in Table 1 . Of the 59 patients screened, 53 were randomized, of which 50 comprised the mITT population ( Figure 2 ). During each treatment period, treatment compliance was .80% or ,120%. 
Efficacy
Pulmonary function sgaw AUC 0-4h sGaw on day 28, following the postmorning dose of SFC250 + TIO, showed significant and clinically meaningful improvements over TIO (15.8%) and SFC250 (28.8%) alone. Ratios of SFC250 + TIO over TIO and SFC250 were statistically significant on days 1 and 28 (Table 2) . SFC250 + TIO also produced improvements in trough and postdose mean sGaw on days 1 and 28 at all timepoints ( Figure 3A ; Tables S1 and S2) with significant differences versus components on day 28. Changes in sRaw reflected those of sGaw (Tables 3, S1, S2) . spirometry SFC250 + TIO and its individual components improved mean FEV 1 over time on days 1 and 28 ( Figure 3B ). On day 28, SFC250 + TIO provided significantly greater improvements in trough FEV 1 compared with TIO and SFC250 (Table 3 ) and in postdose FEV 1 (Tables S3 and S4) . No significant treatment differences were seen on day 1 (Tables S3 and S4 ).
lung volumes
On day 28, SFC250 + TIO provided a significantly greater improvement in trough RV but not in trough IC, TLC, or TGV compared with TIO and SFC250 (Table 3) . On day 28, SFC250 + TIO produced improvements in postdose RV compared to both components ( Figure 3C ). Statistical significance was observed for postdose RV immediately after dosing (time =0) on day 28 for SFC250 + TIO compared to TIO and SFC250 (Tables S3, S4 ). Improvements on day 28 were also seen in postdose TGV, IC, and TLC following treatment with SFC250 + TIO compared to each component, but none were significant (Table S4) . Improvements were seen for all parameters for their adjusted mean values on day 1, but none were significant (Table S3) .
Diary cards and symptoms
Rescue medication usage was similar across all three groups (number of occasions per 24-hour period) for the 70% of patients in the mITT population who were mMRC =1; similar rescue medication usage was also seen in approximately 30% of patients with mMRC $2, although usage was numerically higher than that in the milder group (Table 4) . safety All treatments were well tolerated, with AEs reported by 33% (SFC + TIO), 16% (TIO), and 22% (SFC) of patients (Table 5) . Two serious AEs were reported, both following SFC250 + TIO treatment, and were considered unrelated to the study treatment: prinzmetal angina (one patient) was of moderate intensity and lumbar spinal stenosis (one patient) was of mild intensity.
Discussion
Repeat-dose SFC250 + TIO was more effective in improving sGaw compared to TIO or SFC250, with significant improvements observed on days 1 and 28 up to 4 hours postdose. These improvements were considered clinically relevant and met the primary aim of the study to increase sGaw AUC 0-4h by 15%. This was the first statistically powered study to be performed in Japanese patients with mild COPD investigating the effects of triple therapy on lung function using SFC250. The improvements we saw in sGaw were comparable with those observed in the Western population (22% improvement over TIO and 27% over SFC 50/500 µg alone) studied by Singh et al 4 over 14 days. Although previous studies have investigated the benefits of triple therapy in a Japanese COPD population, 9 this study was the first to use whole-body plethysmography and to include an SFC250 arm to fully evaluate the contribution of TIO under blinded conditions. sGaw is a more sensitive measurement for detecting lung function changes in COPD patients than the more commonly used FEV 1 , therefore, a smaller sample size can be used in clinical trials. 4, 15, 17, 18 Plethysmography is not routinely used in clinical practice or studies due to its complexity, however, as it was used in the study conducted by Singh et al 4 it was important to include it in our study to provide a comparison. It has been postulated that sGaw provides data on the large central airways. [19] [20] [21] Therefore, to give a comprehensive assessment of lung function and lung volumes, we also included the more traditional measurements of FEV 1 and FVC; these describe the more clinically relevant small airways. Improvements in these parameters reflected those of sGaw on day 28 and concurred with previous data using SFC250 11 and SFC 50/500. 4 This is consistent with our finding of a nonsignificant trend in the difference in sGaw between TIO and SFC250 by day 28 (but not day 1), although FEV 1 changes were similar.
Day 28 trough RV, TGV IC, and TLC confirmed that triple therapy was more effective in enhancing lung volume and reducing lung hyperinflation than each individual component, and this was in agreement with previous data. 4 SFC250 + TIO significantly improved trough RV compared to each component, which concurred with other data. 4 TGV represented a novel aspect of our study not measured previously. 4 Improvements were seen in all parameters on day 1 postdose, but significant differences between SFC250 + TIO and SFC250 or TIO alone were only observed for sGaw and its derivative, sRaw.
The majority of patients in this study were mMRC =1 (70%) and did not use rescue medication during the study while on active treatment. Although SFC250 + TIO is widely used, there is limited evidence to support this approach, particularly using FP 250 µg in milder COPD patients of Japanese origin. Published data largely advocate the use of triple therapy in Western COPD populations and using SFC 50/500. 4, 10, [22] [23] [24] A parallel group, 16-week study compared Our study had limitations. It was powered to explore the effect of triple therapy on lung function rather than symptoms and was not designed to look at the effect on exacerbations. Adequately powered studies are now needed to explore the longer term effects of triple therapy, including the impact on symptoms and exacerbation rates. Our observations are relevant to a Japanese population with milder COPD rather than a particular subgroup or phenotype. ICS + LABA is recommended for patients who have risk of exacerbation (GOLD Group C/D); triple therapy is recommended for GOLD group D.
1 However, our study was conducted in patients with a low risk of exacerbation to assess pulmonary function parameters as efficiently as possible: exacerbations can cause daily variation in COPD symptoms, including lung function. Furthermore, exacerbations may increase the risk of patient withdrawal from the study, which would impact outcome validity in a crossover study. The crossover design may also make the safety analysis of each treatment more difficult due to the possibility of carryover effects. Carryover effects on efficacy endpoints were considered unlikely and negligible, so a crossover design had the advantage that each patient was their own control. The study design could not establish when and how symptoms and exacerbations should be used to optimize treatment. A study to answer this question is ongoing. 
Conclusion
SFC250 + TIO treatment for 28 days led to greater improvements in bronchodilation compared with TIO or SFC250 and was well tolerated in Japanese COPD patients. The advantages of triple therapy were observed across a range of physiologically important parameters. Therefore, our study substantiates current knowledge that SFC250 + TIO is more effective than either TIO or SFC250 in improving lung function.
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